[1] ZHANG Z H,HUANG Y,WANG X M,et al.Research advance of small molecular targeted anti-tumor agents TKIs[J] . Chin Prescr Drug(中国处方药),2006,6(51):50-53.
[2] FAIVRE S,DELBALDO C,VERA K,et al. Safety,pharmacokinetic,and antitumor activity of SU11248,a novel oral multitarget tyrosine kinase inhibitor,in patients with cancer[J] . J Clin Oncol,2006,24(1):25-35.
[3] MOTZER R J,MICHAELSON M D,REDMAN B G,et al. Activity of SU11248,a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor,in patients with metastatic renal cell carcinoma[J] . J Clin Oncol,2006,24(1):16-24.
[4] MOTZER R J,RINI B I,BUKOWSKI R M,et al. Sunitinib in patients with metastatic renal cell carcinoma[J] . Jama,2006,295(21):2516-2524.
[5] DEMETRI G D,VAN OOSTEROM A T,GARRETT C R,et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial[J] . Lancet,2006,368(9544):1329-1338.
[6] HAHN O,STADLER W. Sorafenib[J] . Curr Opin Oncol,2006,18(6):615-621.
[7] JAIN L,VENITZ J,FIGG W D. Randomized discontinuation trial of Sorafenib (BAY 43-9006) [J] . Cancer Biol Ther,2006,5(10):1270-1272.
[8] GORE M E,ESCUDIER B. Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma[J] . Oncology (Williston Park),2006,20(6 Suppl 5):19-24.
[9] ABOU-ALFA G K,SCHWARTZ L,RICCI S,et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma[J] . J Clin Oncol,2006,24(26):4293-4300.
[10] EISEN T,AHMAD T,FLAHERTY K T,et al. Sorafenib in advanced melanoma: a phase Ⅱ randomised discontinuation trial analysis[J] . Br J Cancer,2006,95(5):581-586.
[11] HEYMACH J V. ZD6474-clinical experience to date[J] . Br J Cancer,2005,92(Suppl 1):14-20.
[12] LEE D. Pphase Ⅱ data with ZD6474,a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor,in previously treated advanced non-small-cee lung cancer[J] . Clin Lung Cancer,2005,7(2):89-91.
[13] RYAN A J ,WEDGE S R. ZD6474-a novel inhibitor of VEGFR and EGFR tyrosine kinase activity[J] . Br J Cancer,2005,92(Suppl 1):6-13.
[14] LI Y. The multitargeted anti-tumor new angent: ZD6474[J] . Oncol Prog(癌症进展),2006,4(3):206-210.
[15] MILLER K D,TRIGO J M,WHEELER C,et al. A multicenter phase Ⅱ trial of ZD6474,a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor,in patientswith previously treated metastatic breast cancer[J] . Clin Cancer Res,2005,11(9):3369-3376.
[16] TALPAZ M,SHAH N P,KANTARJIAN H,et al. Dasatinib in imatinib-resistant philadelphia chromosome-positive leukemias[J] . New Eng J Med,2006,354(24):2531-2541.
[17] ROBOZ G J,GILES F J,LIST A F,et al. Phase 1 study of PTK787/ZK 222584,a small molecule tyrosine kinase receptor inhibitor,for the treatment of acute myeloid leukemia and myelodysplastic syndrome[J] . Leukemia,2006,20(6):952-957.
[18] TYAGI P. Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial[J] . Clin Colorectal Cancer,2005,5(1):24-26.
[19] ZHONG Y,LI Z Y,YOU Q D. Investigations in vascular endothelial growth factor receptor family tyrosine kinase inhibitor[J] . Chin New Drugs J(中国新药杂志),2006,15(3):181-185.
[20] ZHOU H,KIM Y S,PELETIER A,et al. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation,radiosensitization,and resistance[J] . Int J Radiat Oncol Biol Phys,2004,58(2):344-352.
[21] BENCE A K,ANDERSON E B,HALEPOTA M A,et al. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016,a dual EGFR-ErbB2 inhibitor,in healthy subjects[J] . Invest New Drugs,2005,23(1):39-49.
[22] PATYNA S,LAIRD A D,MENDEL D B,et al. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity[J] . Mol Cancer Ther,2006,5(7):1774-1782.
[23] ALBERT D H,TAPANG P,MAGOC T J,et al. Preclinical activity of ABT-869,a multitargeted receptor tyrosine kinase inhibitor[J] . Mol Cancer Ther,2006,5(4):995-1006.
[24] KUENEN B C,GIACCONE G,RUIJTER R,et al. Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies[J] . Clin Cancer Res,2005,11(17):6240-6246.
[25] WANG J,SHI Y K. Research developments for gastrointestinal stromal tumors [J] . Chin Prescr Drug(中国处方药),2006,8(53):34-37.